A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community.
We compared 40 patients taking lomefloxacin 400 mg once daily for 5 days in a double blind trial with 44 placebo takers with proven community acquired bacterial diarrhoea (85% due to Campylobacter spp.). Lomefloxacin eradicated Campylobacter spp. in 75% but did not alter clinical outcome. Twenty-eight per cent of the campylobacter isolates developed resistance. Thirty-three per cent developed side-effects. Lomefloxacin is not recommended for community-acquired bacterial diarrhoea when Campylobacter spp. predominate.
Ellis-Pegler
R B
RB
Infectious Disease Unit, Auckland Hospital, New Zealand.
Hyman
L K
LK
Ingram
R J
RJ
McCarthy
M
M
D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002167:Campylobacter / Q000187:drug effects; D002169:Campylobacter Infections / Q000188:drug therapy / Q000382:microbiology; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D005243:Feces / Q000166:cytology / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin